Download PDF
Thorac Cardiovasc Surg 2023; 71(06): 469-482
DOI: 10.1055/s-0042-1748768
Original Cardiovascular

The Association between Glycosylated Hemoglobin Level and Platelets Reactivity in Patients with Diabetes Mellitus Undergoing Elective Coronary Artery Bypass Grafting

Martina Zrno Mihaljevic 
1   Department of Cardiovascular Diseases, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia
,
Mate Petricevic 
2   Department of Cardiac Surgery, University Department of Health Studies, University of Split, UHC Zagreb, Split, Croatia
,
Sanja Konosic
3   Department of Anesthesiology, University Clinical Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia
,
Lucija Svetina
4   Department of Cardiac Surgery, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia
,
Marjan Urlic
1   Department of Cardiovascular Diseases, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia
,
Zrinka Starcevic
1   Department of Cardiovascular Diseases, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia
,
Kristina Krzelj
4   Department of Cardiac Surgery, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia
,
Milan Milosevic
5   Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia
,
Viktor Kalamar
6   Department of Thoracic Surgery, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
,
Hrvoje Gasparovic 
4   Department of Cardiac Surgery, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia
,
Bojan Biocina
7   Department of Cardiac Surgery, University Clinical Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia
› Author Affiliations
› Further Information
    Permissions and Reprints All articles of this category

Abstract

Background Diabetic patients tend to have increased platelet reactivity after coronary artery bypass grafting (CABG). The aim of this study was to determine the association between hemoglobin A1c (HbA1c) values and platelet reactivity and to evaluate the consequent impact on clinical outcomes in patients undergoing CABG.

Methods This prospective observational trial consecutively enrolled 225 diabetic patients undergoing CABG, between February 2014 and October 2018. HbA1c levels and platelet function (multiple electrode aggregometry [MEA]) were analyzed the day before surgery and on postoperative day 4 (POD 4). Patients were divided into two groups according to the HbA1c value: HBA1c < 7% and HbA1c ≥ 7%.

Results Significantly higher postoperative ASPI (platelet function test based on arachidonic acid) and ADP (platelet function test based on adenosine diphosphate) test values were observed at POD 4 compared with preoperative values (ASPI test: p < 0.001; ADP test: p < 0.001). The prevalence of preoperative aspirin resistance (AR) was 46.4% relative to 57.2% after surgery showing consistent increase in postoperative AR by approximately 10%. In addition, the prevalence of AR in the HbA1c < 7% group was higher by 10% compared with the HbA1c ≥ 7% group, both before and after surgery. We did not demonstrate differences in clinical outcomes between the HbA1c groups.

Conclusion Perioperative assessment of platelet reactivity in diabetic patients detects those with AR who may be at increased risk of adverse ischemic events. A personalized approach guided by MEA and administration of early and more potent antiaggregation therapy after CABG can be beneficial in this group of patients.

Keywords

coronary artery bypass grafting - HbA1c - multiple electrode aggregometry - aspirin resistance

Authors' Contribution

M.Z.M., M.P., S.K., M.U., H.G., B. B. contributed most to the work, including drafting the manuscript and revising it critically for important intellectual content. M.Z.M., M.P., S.K., L.S., M.M., H.G., B.B. made Substantial contributions to the Conception or design of the work. M.Z.M., M.P., S.K. L.S., Z.S., V.K., H.G., B.B. contributed to Literature overview, data acquisition, analysis, and interpretation of data. M.Z.M., M.P., M.U., Z.S., M.M., H.G., B.B. contributed to the Figures. All authors drafted the work for important intellectual content and approved the final version and are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.




Publication History

Received: 29 November 2021

Accepted: 29 March 2022

Article published online:
25 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Schramm TK, Gislason GH, Køber L. et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117 (15) 1945-1954
    CrossrefPubMedGoogle Scholar
  • 2 Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108 (12) 1527-1532
    CrossrefPubMedGoogle Scholar
  • 3 Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26 (12) 3264-3272
    CrossrefPubMedGoogle Scholar
  • 4 Abaci A, Caliskan M, Bayram F. et al. A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors. Platelets 2006; 17 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 5 Winocour PD. Platelet turnover in advanced diabetes. Eur J Clin Invest 1994; 24 (Suppl. 01) 34-37
    CrossrefPubMedGoogle Scholar
  • 6 Watala C, Pluta J, Golanski J. et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl) 2005; 83 (02) 148-158
    CrossrefPubMedGoogle Scholar
  • 7 Serruys PW, Morice MC, Kappetein AP. et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360 (10) 961-972
    CrossrefPubMedGoogle Scholar
  • 8 Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg 2008; 34 (01) 93-108
    CrossrefPubMedGoogle Scholar
  • 9 Petricevic M, Biocina B, Konosic S, Kopjar T, Kunac N, Gasparovic H. Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy. Heart Vessels 2013; 28 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 10 Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010; 56 (20) 1639-1643
    CrossrefPubMedGoogle Scholar
  • 11 Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J 2006; 27 (23) 2900 , author reply 2900–2901
    CrossrefPubMedGoogle Scholar
  • 12 Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009; 158 (05) 784.e1-784.e6
    CrossrefPubMedGoogle Scholar
  • 13 Knapik P, Cieśla D, Filipiak K, Knapik M, Zembala M. Prevalence and clinical significance of elevated preoperative glycosylated hemoglobin in diabetic patients scheduled for coronary artery surgery. Eur J Cardiothorac Surg 2011; 39 (04) 484-489
    CrossrefPubMedGoogle Scholar
  • 14 Petricevic M, Biocina B. Prevalence and clinical significance of elevated preoperative glycosylated hemoglobin in diabetic patients scheduled for coronary artery surgery. Eur J Cardiothorac Surg 2012; 41 (02) 469-470 , author reply 470
    CrossrefPubMedGoogle Scholar
  • 15 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 (9596): 1453-1457
    CrossrefPubMedGoogle Scholar
  • 16 American Diabetes A. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl. 01) S4-S36
    PubMedGoogle Scholar
  • 17 Petricević M, Biocina B, Konosić S. et al. Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery. Coll Antropol 2013; 37 (03) 833-839
    PubMedGoogle Scholar
  • 18 Thygesen K, Alpert JS, White HD. et al; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 116 (22) 2634-2653
    CrossrefPubMedGoogle Scholar
  • 19 Sacco RL, Adams R, Albers G. et al; American Heart Association, American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention, American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37 (02) 577-617
    CrossrefPubMedGoogle Scholar
  • 20 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 21 Halkos ME, Lattouf OM, Puskas JD. et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg 2008; 86 (05) 1431-1437
    CrossrefPubMedGoogle Scholar
  • 22 Halkos ME, Puskas JD, Lattouf OM. et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2008; 136 (03) 631-640
    CrossrefPubMedGoogle Scholar
  • 23 Kim HJ, Shim JK, Youn YN, Song JW, Lee H, Kwak YL. Influence of preoperative hemoglobin A1c on early outcomes in patients with diabetes mellitus undergoing off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg 2020; 159 (02) 568-576
    CrossrefPubMedGoogle Scholar
  • 24 Huang Z, Liu Y, Mao Y, Chen W, Xiao Z, Yu Y. Relationship between glycated haemoglobin concentration and erythrocyte survival in type 2 diabetes mellitus determined by a modified carbon monoxide breath test. J Breath Res 2018; 12 (02) 026004
    CrossrefPubMedGoogle Scholar
  • 25 Collaborative overview of randomised trials of antiplatelet therapy–II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308 (6922): 159-168
    CrossrefPubMedGoogle Scholar
  • 26 Dunning J, Versteegh M, Fabbri A. et al; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34 (01) 73-92
    CrossrefPubMedGoogle Scholar
  • 27 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134 (10) e123-e155
    CrossrefPubMedGoogle Scholar
  • 28 Campeau L, Enjalbert M, Lespérance J. et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311 (21) 1329-1332
    CrossrefPubMedGoogle Scholar
  • 29 Estrada CA, Young JA, Nifong LW, Chitwood Jr WR. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003; 75 (05) 1392-1399
    CrossrefPubMedGoogle Scholar
  • 30 Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123 (07) 798-813
    CrossrefPubMedGoogle Scholar
  • 31 Mori M, Shioda K, Bin Mahmood SU, Mangi AA, Yun JJ, Geirsson A. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting. Ann Cardiothorac Surg 2018; 7 (05) 628-635
    CrossrefPubMedGoogle Scholar
  • 32 van Diepen S, Fuster V, Verma S. et al. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM Insights. J Am Coll Cardiol 2017; 69 (02) 119-127
    CrossrefPubMedGoogle Scholar
  • 33 Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther 2018; 8 (05) 594-609
    CrossrefPubMedGoogle Scholar